GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) – Equities researchers at Roth Capital issued their FY2029 earnings per share (EPS) estimates for shares of GT Biopharma in a note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff anticipates that the company will earn $0.33 per share for the year. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for GT Biopharma’s current full-year earnings is ($6.79) per share.
Separately, Roth Mkm started coverage on shares of GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective for the company.
GT Biopharma Stock Performance
Shares of NASDAQ:GTBP opened at $2.30 on Thursday. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66. The company’s fifty day moving average is $2.43 and its 200-day moving average is $2.47.
GT Biopharma Company Profile
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
Further Reading
- Five stocks we like better than GT Biopharma
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Investing in Commodities: What Are They? How to Invest in Them
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.